### HIGHLIGHTS

1793  Selected Articles from This Issue

### CANCER GENES AND NETWORKS

1802  Bidirectional Regulatory Cross-Talk between Cell Context and Genomic Aberrations Shapes Breast Tumorigenesis  
Brijesh Kumar, Poornima Bhat-Nakshatri, Cali Maguire, Max Jacobsen, Constance J. Temm, George Sandusky, and Harikrishna Nakshatri

1818  Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment  
Hitoshi Shiotani, Artyom A. Alekseyenko, Zhipeng A. Wang, Ivona Filic, Tatiana M. Knox, Nghi M. Luong, Yeying Huang, David A. Scott, Kristen L. Jones, Pratulca C. Gokhale, Madeleine E. Lemieux, Philip A. Cole, Mitzi I. Kuroda, and Christopher A. French

### CANCER “-OMICS”

1840  Heterogeneity and Cancer-Related Features in Lymphangioleiomyomatosis Cells and Tissue  
Roderic Espín, Alexandra Baiges, Eline Blommaert, Carmen Herranz, Antonio Roman, Berta Saez, Julio Ancochea, Claudia Valenzuela, Piedad Usetti, Rosalía Laporta, José A. Rodríguez-Portal, Coline H.M. van Moorsel, Joanne J. van der Vis, Marian J.R. Quanjel, Anna Villar-Piqué, Daniela Díaz-Lucena, Franc Llorens, Álvaro Casanova, María Molina-Molina, Mireya Plass, Francesca Mateo, Joël Moss, and Miquel Angé Pujana

1854  Longitudinal Analysis of Human Pancreatic Adenocarcinoma Development Reveals Transient Gene Expression Signatures  
Jungsun Kim, Taelor Ekstrom, Wenli Yang, Greg Donahue, Dmytro Grygoryev, Thuy T.M. Ngo, John L. Muschler, Terry Morgan, and Kenneth S. Zaret

1868  N-Glycosylation Patterns Correlate with Hepatocellular Carcinoma Genetic Subtypes  
Andrew DelaCourt, Alyson Black, Peggi Angel, Richard Drake, Yujiin Hoshida, Amit Singal, David Lewin, Bachir Taouli, Sara Lewis, Myron Schwarz, M. Isabel Fiel, and Anand S. Mehta

### CELL FATE DECISIONS

1878  Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence  
Daqian Zhan, Ding Ma, Shuang Wei, Bachchu Lal, Yi Fu, Charles Eberhart, John Laterra, Mingyao Ying, Yunqing Li, Alan Meeker, Hernando Lopez-Bertoni, and Shuli Xia

### GENOME MAINTENANCE

1889  The PI3K/mTOR Inhibitor Ompalisib Suppresses Nonhomologous End Joining and Sensitizes Cancer Cells to Radio- and Chemotherapy  
Jie Du, Fuqiang Chen, Jiahua Yu, Lijun Jiang, and Meijuan Zhou
# Table of Contents

## Metabolism

1900  Mutant p53 Attenuates Oxidative Phosphorylation and Facilitates Cancer Stemness through Downregulating miR-200c-PCK2 Axis in Basal-Like Breast Cancer  
Chii-Hong Chao, Chen-Yun Wang, Cing-Hong Wang,  
Ting-Wen Chen, Huiai-Yu Hsu, Hao-Wei Huang,  
Chia-Wei Li, and Ru-Tsun Mai

## New Horizons in Cancer Biology

1917  Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling  
Michael H. McGuire, Santosh K. Dasari, Hui Yao,  
Yunfei Wen, Lingegowda S. Mangala, Emine Bayraktar,  
Wencai Ma, Cristina Ivan, Einaev Shoshann,  
Sherry Y. Wu, Eric Jonasch, Menashe Bar-Eli,  
Jing Wang, Keith A. Baggerly, and Anil K. Sood

1929  NP-ALT, a Liposomal:Peptide Drug, Blocks p27Kip1 Phosphorylation to Induce Oxidative Stress, Necroptosis, and Regression in Therapy-Resistant Breast Cancer Cells  
Irina Jilishtiz, Jason Luis Quiñones, Priyank Patel,  
Grace Chen, Jared Pasetsky, Allison VanInwegen,  
Scott Schoninger, Manasi P. Jogalekar,  
Vladislav Tsiiperson, Lingyue Yan, Yun Wu,  
Susan R.S. Gottesman, Jonathan Somma, and  
Stacy W. Blain

## Signal Transduction and Functional Imaging

1946  SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer  
Elisha Martin and Yehenew M. Agazie

## Tumor Microenvironment and Immunobiology

1957  ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression  
Helen Sheldon, Esther Bridges, Ildefonso Silva,  
Massimo Masiero, David M. Favara, Dian Wang,  
Russell Leek, Cameron Snell, Ioannis Roxanis,  
Mira Kreuzer, Uzi Gileadi, Francesca M. Buffa,  
Alison Banham, and Adrian L. Harris

## About the Cover

Sonic Hedgehog medulloblastoma (SHH-MB) is the most prevalent molecular subtype of medulloblastoma, a common and deadly pediatric brain malignancy. Significant effort has been invested into preclinical development of inhibitors directed at downstream targets of the SHH pathway, such as the stem cell factor and proto-oncogene SOX9. The cover depicts immunofluorescence imaging of SHH-MB mouse tumor models, in which SOX9 expression is labeled in red and the glial marker GFAP is labeled in green. The authors demonstrate that, even though SOX9 expression is an intrinsic feature of SHH-MB that is not shared by other medulloblastoma subtypes, interference with SOX9 expression did not significantly alter SHH-MB development or disease course. They therefore argue that efforts to develop SOX9 inhibitors for clinical use will likely not provide significant benefit for SHH-MB patients if advanced to the clinic, and suggest that alternative targets must be identified. For more information, see the Highlight on page 1793 and the article on page 1831.

DOI: 10.1158/1541-7786.MCR-19-11-CVR
Molecular Cancer Research

19 (11)


Updated version
Access the most recent version of this article at:
http://mcr.aacrjournals.org/content/19/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://mcr.aacrjournals.org/content/19/11. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.